# Commission Regulation (EU) No 378/2012 of 3 May 2012 refusing to authorise certain health claims made on foods and referring to the reduction of disease risk and to children's development and health (Text with EEA relevance), Annex

Extent: E+W+S+N.I.

Rejected health claims
Application – Relevant provisions of Regulation (EC) No 1924/2006
Nutrient, substance, food or food category
Claim
EFSA opinion reference
Article 14(1)(a) health claim referring to a reduction of a disease risk
ProteQuine®
ProteQuine® elevates/maintains the level of ScIgA on mucous membranes. Decreased or insufficient level of ScIgA is a risk factor in the development of common cold or influenza
Q-2008-397
Article 14(1)(a) health claim referring to a reduction of a disease risk
ProteQuine® in combination with bovine lactoferrin
ProteQuine® in combination with bovine lactoferrin elevates/maintains the level of ScIgA on mucous membranes. Decreased or insufficient level of ScIgA is a risk factor in the development of common cold with sore throat and combination of ProteQuine® with bovine lactoferrin reduces the risk of the development of sore throat
Q-2008-398
Article 14(1)(b) health claim referring to children's development and health
Lactobacillus delbrueckii subsp. bulgaricus strain AY/CSL (LMG P-17224) and Streptococcus thermophilus strain 9Y/CSL (LMG P-17225)
Maintaining the gut health by normalizing the intestinal flora
Q-2008-273
Article 14(1)(b) health claim referring to children's development and health
Beta palmitate
Beta palmitate enrichment contributes to increase calcium absorption
Q-2008-172

---
Source: https://www.legislation.gov.uk/eur/2012/378/annex (the official version)
Page: https://openlegislation.uk/eu-regulation-2012-378/annex
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.